{"product_id":"coherus-five-forces-analysis","title":"Coherus Biosciences Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eA Must-Have Tool for Decision-Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCoherus Biosciences operates in a dynamic biopharmaceutical landscape, where the threat of new entrants is moderate due to high R\u0026amp;D costs and regulatory hurdles, but the bargaining power of buyers, particularly large payers, can significantly impact pricing. Understanding these forces is crucial for strategic planning.\u003c\/p\u003e\n\u003cp\u003eThe complete report reveals the real forces shaping Coherus Biosciences’s industry—from supplier influence to threat of new entrants. Gain actionable insights to drive smarter decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Manufacturing and API Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCoherus BioSciences, like many biopharma firms, depends on specialized contract manufacturing organizations (CMOs) for critical production steps, including active pharmaceutical ingredients (APIs) and final product assembly. The scarcity of CMOs possessing the required advanced expertise and stringent regulatory approvals for complex biologics and oncology drugs grants these suppliers considerable bargaining power.\u003c\/p\u003e\n\u003cp\u003eAny limitations in manufacturing capacity or prior commitments by these specialized CMOs can directly affect product availability and Coherus's revenue streams. This was evident with the temporary UDENYCA supply interruption experienced in late 2024, underscoring the vital importance of these supplier relationships and their capacity to influence Coherus's operational continuity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Technology and Equipment Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers of advanced biotechnology equipment, specialized reagents, and proprietary cell lines wield significant influence over Coherus Biosciences. Their offerings are often unique and patented, making it difficult for Coherus to find readily available alternatives. For instance, the cost of specialized bioreactors or unique cell culture media can represent a substantial portion of a drug's manufacturing expenses.\u003c\/p\u003e\n\u003cp\u003eThe switching costs associated with these critical inputs are notably high. This is due to the substantial capital investment required for new equipment, the rigorous validation processes needed to ensure product quality and regulatory compliance, and the extensive training personnel must undergo. This dependency directly impacts Coherus's input costs and can restrict its manufacturing agility.\u003c\/p\u003e\n\u003cp\u003eTo counter this supplier power, Coherus can explore strategies such as negotiating long-term supply agreements to lock in pricing and ensure availability. Diversifying its sources for essential equipment and reagents, where feasible, also serves to reduce reliance on any single supplier, thereby strengthening its bargaining position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Service Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe drug development journey, especially for cutting-edge oncology treatments, is intricate and time-consuming. This complexity demands specialized R\u0026amp;D services from entities like Contract Research Organizations (CROs), preclinical testing labs, and data management firms.\u003c\/p\u003e\n\u003cp\u003eThe high level of expertise and strict regulatory adherence needed for these services means there's a limited pool of highly respected providers. This scarcity gives these suppliers significant leverage, impacting both the pace and expense of Coherus's pipeline advancement.\u003c\/p\u003e\n\u003cp\u003eCoherus's current clinical trials, such as those for CHS-114 and casdozokitug, are heavily dependent on the capabilities of these external R\u0026amp;D partners.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Licensors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntellectual property licensors wield significant bargaining power, especially when Coherus Biosciences relies on in-licensed technologies or molecules for its biosimilar and oncology products. These agreements often dictate royalty rates and milestone payments, directly influencing Coherus's financial performance. For instance, the 2023 divestiture of UDENYCA involved transferring associated licensing agreements, highlighting the impact of such contractual terms on strategic decisions.\u003c\/p\u003e\n\u003cp\u003eThe terms of these licensing deals can be highly favorable to the licensor, particularly if the licensed IP is critical to Coherus's product pipeline or market entry. This leverage allows licensors to command substantial upfront fees, ongoing royalties, and even equity stakes. As of early 2024, the biosimilar market continues to see intense competition, making access to differentiated or first-to-market technologies through licensing even more valuable, thereby strengthening licensor power.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eCritical IP dependence:\u003c\/strong\u003e Coherus's reliance on licensed intellectual property for key products grants licensors considerable leverage.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRoyalty and milestone structures:\u003c\/strong\u003e Favorable terms for licensors can significantly impact Coherus's cost of goods sold and profitability.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic divestitures:\u003c\/strong\u003e The transfer of licensing agreements during asset sales, like the UDENYCA divestiture, underscores the importance of these contracts.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket dynamics:\u003c\/strong\u003e The competitive landscape in biosimilars and oncology can amplify the bargaining power of IP holders.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTalent and Human Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe biopharmaceutical sector, especially in areas like oncology drug development, faces a significant challenge in securing specialized talent.  This scarcity directly translates to increased bargaining power for skilled employees.  For instance, in 2024, the demand for experienced oncology researchers and regulatory affairs specialists remained exceptionally high, driving up salary expectations and retention costs for companies like Coherus Biosciences.\u003c\/p\u003e\n\u003cp\u003eThe bargaining power of talent is amplified by the niche expertise required. Professionals with proven track records in biosimilar commercialization or complex clinical trial management can command premium compensation packages. This directly impacts Coherus's operating expenses, as attracting and retaining such individuals necessitates competitive remuneration and benefits.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eTalent Scarcity:\u003c\/strong\u003e High demand for specialized skills in oncology and biosimil development grants employees significant leverage.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIncreased Costs:\u003c\/strong\u003e Top talent acquisition and retention efforts drive up compensation and benefits, impacting operating expenses.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Workforce Management:\u003c\/strong\u003e Coherus's organizational streamlining, including workforce adjustments, reflects a deliberate approach to managing human capital costs and aligning with its oncology focus.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier Power: A Critical Factor in Biotech Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe bargaining power of suppliers for Coherus Biosciences is significant, particularly for specialized contract manufacturing organizations (CMOs) and providers of advanced biotechnology equipment. These suppliers often possess unique expertise and regulatory approvals, making alternatives scarce and switching costs high.\u003c\/p\u003e\n\u003cp\u003eThis dependence was highlighted by a UDENYCA supply interruption in late 2024, demonstrating how supplier capacity and commitments directly impact Coherus's revenue and operations. The cost of specialized inputs, like bioreactors or cell culture media, can also represent a substantial portion of manufacturing expenses.\u003c\/p\u003e\n\u003cp\u003eTo mitigate this, Coherus can pursue long-term supply agreements and diversify its supplier base where possible, thereby enhancing its negotiation position and ensuring continuity.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThis analysis unpacks the competitive forces impacting Coherus Biosciences, examining the threat of new entrants, the bargaining power of buyers and suppliers, the threat of substitutes, and the intensity of rivalry within the biopharmaceutical market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCoherus Biosciences' Porter's Five Forces analysis provides a clear, one-sheet summary of competitive pressures, offering instant clarity for strategic decision-making and pain point relief in understanding market dynamics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Systems and Pharmacy Benefit Managers (PBMs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHealthcare systems and Pharmacy Benefit Managers (PBMs) hold considerable sway over Coherus Biosciences due to their substantial purchasing power. These entities, acting as major buyers, can negotiate aggressively on price and terms, directly influencing Coherus's profitability. For instance, PBMs manage drug formularies, deciding which medications are preferred, and their decisions can significantly impact a biosimilar's market access and adoption. In 2024, the increasing consolidation among PBMs, with the top three PBMs covering a significant portion of insured Americans, amplifies their bargaining leverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers and Reimbursement Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGovernment payers like Medicare and private insurers wield considerable influence through their reimbursement and coverage decisions. For biosimilars, including those Coherus is involved with, these policies are critical, directly impacting market uptake and financial success. For example, Medicare reimbursement rates can sometimes favor established, higher-priced reference products, which can make biosimilars less appealing to healthcare providers and patients.\u003c\/p\u003e\n\u003cp\u003eThe increasing emphasis on oncology within Coherus's strategy necessitates a deep understanding of the intricate reimbursement pathways prevalent in cancer care. Navigating these complex oncology reimbursement landscapes is a key challenge, as policies here can significantly shape the economic viability of biosimilar treatments in this high-value therapeutic area.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysicians and Prescribers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePhysicians and other prescribers hold significant sway in determining which medications patients receive, often showing a strong preference for well-established biologic drugs. This brand loyalty can be a hurdle for biosimilars, even with clear evidence of similarity and potential cost reductions.  For instance, in 2023, the U.S. biosimilar market penetration for biologics was still developing, with some therapeutic areas seeing lower adoption rates than anticipated, highlighting the need for physician education.\u003c\/p\u003e\n\u003cp\u003eCoherus Biosciences faces the challenge of overcoming this ingrained loyalty by investing in comprehensive education for healthcare providers regarding the clinical value and safety of its biosimilars. This is crucial as they aim to increase the uptake of products like their oncology treatment, LOQTORZI, by demonstrating its efficacy and differentiating it in a competitive landscape.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Groups and Patient Preferences\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatient advocacy groups and individual patient preferences significantly influence the bargaining power of customers in the biosimilar market. Patients, guided by these groups and personal experiences, can either embrace or resist biosimilar treatments. This resistance often stems from concerns about efficacy, potential side effects, or a general lack of understanding regarding biosimilars, leading them to favor established reference products.  For instance, a 2024 survey indicated that while awareness of biosimilars is growing, a notable percentage of patients still express reservations about switching from their current medications due to perceived risks.\u003c\/p\u003e\n\u003cp\u003eCoherus Biosciences' ability to foster trust among patients and their advocates is paramount. Demonstrating that their biosimilar products are not only high-quality and safe but also as effective as their reference counterparts is crucial for overcoming patient hesitancy. The company's stated mission to expand access to affordable, high-quality therapeutics directly addresses this by emphasizing the value proposition to patients.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatient Preferences:\u003c\/strong\u003e Patients' willingness to switch to biosimilars is a key factor.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAdvocacy Group Influence:\u003c\/strong\u003e Patient advocacy groups can shape perceptions and drive demand or resistance.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTrust and Perception:\u003c\/strong\u003e Coherus must build confidence in the safety and efficacy of its biosimilars.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAccess and Affordability:\u003c\/strong\u003e The company's focus on these aspects aims to increase patient acceptance.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGroup Purchasing Organizations (GPOs) and Integrated Delivery Networks (IDNs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLarge Group Purchasing Organizations (GPOs) and Integrated Delivery Networks (IDNs) wield considerable influence by consolidating the purchasing power of numerous healthcare providers. This aggregation allows them to negotiate significant price reductions from pharmaceutical manufacturers like Coherus Biosciences. For instance, in 2024, major GPOs reported managing purchasing for thousands of hospitals and healthcare facilities, representing billions of dollars in annual spending.\u003c\/p\u003e\n\u003cp\u003eCoherus must actively compete within these GPO and IDN frameworks to secure contracts and ensure market access for its biosimilar and oncology products. The pressure to gain formulary placement and secure volume-based agreements means these powerful entities directly shape Coherus's sales and pricing strategies. This bargaining power is a critical consideration, particularly for biosimil competitors aiming to displace originator drugs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eAggregated Purchasing Power:\u003c\/strong\u003e GPOs and IDNs represent a consolidated demand, enabling them to negotiate substantial discounts.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eContract Negotiation:\u003c\/strong\u003e Coherus faces intense competition to win contracts within these purchasing groups.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInfluence on Pricing and Sales:\u003c\/strong\u003e Formulary placement and volume agreements dictated by GPOs\/IDNs significantly impact Coherus's revenue.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiosimilar Market Impact:\u003c\/strong\u003e This factor is especially crucial for biosimil manufacturers seeking to compete on price and access.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCustomer Power Dictates Coherus Biosimilar Market Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe bargaining power of customers for Coherus Biosciences is substantial, primarily driven by large purchasers like Pharmacy Benefit Managers (PBMs) and government payers who can dictate terms and pricing. In 2024, the consolidation of PBMs, with the top three entities covering a significant majority of insured Americans, intensifies their leverage. This allows them to negotiate aggressively on price and formulary placement, directly impacting Coherus's profitability and market access for biosimilars.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCustomer Segment\u003c\/th\u003e\n\u003cth\u003eBargaining Power Drivers\u003c\/th\u003e\n\u003cth\u003eImpact on Coherus Biosciences (2024 Focus)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBMs \u0026amp; Insurers\u003c\/td\u003e\n\u003ctd\u003eConsolidated purchasing, formulary control, reimbursement policies\u003c\/td\u003e\n\u003ctd\u003eSignificant price pressure, market access challenges for biosimilars\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup Purchasing Organizations (GPOs) \u0026amp; IDNs\u003c\/td\u003e\n\u003ctd\u003eAggregated demand, volume-based contract negotiation\u003c\/td\u003e\n\u003ctd\u003eIntense competition for contracts, pressure on pricing and sales strategies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhysicians \u0026amp; Patients\u003c\/td\u003e\n\u003ctd\u003eBrand loyalty, preference for established biologics, trust\/perception of biosimilars\u003c\/td\u003e\n\u003ctd\u003eHurdles for biosimilar adoption, need for extensive education and trust-building\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eCoherus Biosciences Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview showcases the complete Coherus Biosciences Porter's Five Forces Analysis, providing a detailed examination of competitive rivalry, the threat of new entrants, the bargaining power of buyers and suppliers, and the threat of substitute products. The document displayed here is the part of the full version you’ll get—ready for download and use the moment you buy, offering actionable insights into Coherus's market landscape.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55611679211897,"sku":"coherus-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/coherus-five-forces-analysis.png?v=1754761088","url":"https:\/\/growthsharematrix.com\/products\/coherus-five-forces-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}